Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00179660Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2005
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in non-Hodgkin lymphoma (NHL), sponsored by Celgene Corporation. Primary endpoint: Percentage of Participants With Response. Started Aug 2005; status: completed.
02
Drugs
lenalidomide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00179660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00179660.